Back to top

Tale of the Tape

Zacks Equity Research

Kite Pharma (KITE) Looks Good: Stock Adds 7% in Session
November 08, 2016

ANIK KITE

Trades from $3

Kite Pharma, Inc. (KITE - Free Report) was a big mover last session, as the company saw its shares rise 7% on the day. The move came on solid volume with far more shares changing hands than in a normal trading session. This reverses the recent downtrend for the company as the stock is now down almost 21% in the past one-month time frame.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.      

Kite Pharma currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.

A better-ranked Bio-Medical/Gene stock is Anika Therapeutics Inc. (ANIK - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is KITE going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.  Click to see them now>>